Demographics and cytogenetic characteristics of all patients
| . | Total (N = 52) . | R140-m (n = 33) . | R172-m (n = 19) . | P value∗ . |
|---|---|---|---|---|
| Age, median (IQR) | 63 (53-68) | 62 (52-68) | 64 (60-67) | .4 |
| Sex, female | 28 (54%) | 16 (48%) | 12 (63%) | .3 |
| Race | .1 | |||
| White | 37 (82%) | 25 (89%) | 12 (71%) | |
| Asian | 5 (11%) | 3 (11%) | 2 (12%) | |
| Black | 3 (6.7%) | 0 | 3 (18%) | |
| Unknown | 7 | 5 | 2 | |
| Blast percentage at diagnosis, median (IQR) | 55 (33-70) | 53 (23-67) | 60 (43-75) | .082 |
| ELN 2022 riskcategory | <.001 | |||
| Favorable | 13 (25%) | 13 (39%) | 0 | |
| Intermediate | 10 (19%) | 3 (9.1%) | 7 (37%) | |
| Adverse | 29 (56%) | 17 (52%) | 12 (63%) | |
| AML classification(ICC 202220 ) | <.001 | |||
| AML with recurrent genetic abnormalities | 14 (27%) | 14 (42%) | 0 | |
| AML with MDS-related gene mutations | 26 (50%) | 14 (42%) | 12 (63%) | |
| MDS/AML with MDS-related gene mutations | 4 (7.7%) | 4 (12%) | 0 | |
| AML with MDS-related cytogenetic abnormalities | 2 (3.8%) | 1 (3%) | 1 (5.3%) | |
| AML, NOS | 6 (12%) | 0 | 6 (32%) | |
| Cytogenetics | ||||
| Normal karyotype | 24 (46%) | 16 (48%) | 8 (42%) | .7 |
| Other karyotypes | ||||
| Trisomy 8 | 8 (15%) | 4 (12%) | 4 (21%) | .4 |
| Trisomy 11 | 4 (7.7%) | 2 (6.1%) | 2 (11%) | .6 |
| Trisomy 21 | 2 (3.8%) | 2 (6.1%) | 0 | .5 |
| Monosomy 7 | 2 (3.8%) | 2 (6.1%) | 0 | .5 |
| Molecular | ||||
| NPM1 | 13 (25%) | 13 (39%) | 0 | .002 |
| FLT3 | 3 (5.8%) | 3 (9%) | 0 | .3 |
| DNMT3A | 22 (44%) | 14 (45%) | 8 (42%) | .8 |
| RUNX1 | 15 (30%) | 10 (32%) | 5 (26%) | .7 |
| NRAS | 5 (10%) | 5 (16%) | 0 | .14 |
| BCOR | 10 (26%) | 4 (18%) | 6 (38%) | .3 |
| SRSF2 | 14 (38%) | 12 (55%) | 2 (13%) | .011 |
| ASXL1 | 8 (16%) | 5 (16%) | 3 (16%) | >.9 |
| Induction regimen | .8 | |||
| 7+3 | 28 (54%) | 17 (52%) | 11 (59%) | |
| 7+3+enasidenib | 11 (21%) | 7 (21%) | 4 (21%) | |
| 7+3+FLT3 inhibitor | 5 (10%) | 3 (9%) | 2 (10%) | |
| CPX-351 | 8 (15%) | 6 (18%) | 2 (10%) | |
| Induction intensity | .8 | |||
| Dauno60 | 30 (58%) | 18 (54%) | 12 (63%) | |
| Dauno90 | 12 (23%) | 8 (24%) | 4 (21%) | |
| Idarubicin 12 | 2 (4%) | 1 (3%) | 1 (5%) | |
| CPX-351 | 8 (15%) | 6 (18%) | 2 (11%) | |
| . | Total (N = 52) . | R140-m (n = 33) . | R172-m (n = 19) . | P value∗ . |
|---|---|---|---|---|
| Age, median (IQR) | 63 (53-68) | 62 (52-68) | 64 (60-67) | .4 |
| Sex, female | 28 (54%) | 16 (48%) | 12 (63%) | .3 |
| Race | .1 | |||
| White | 37 (82%) | 25 (89%) | 12 (71%) | |
| Asian | 5 (11%) | 3 (11%) | 2 (12%) | |
| Black | 3 (6.7%) | 0 | 3 (18%) | |
| Unknown | 7 | 5 | 2 | |
| Blast percentage at diagnosis, median (IQR) | 55 (33-70) | 53 (23-67) | 60 (43-75) | .082 |
| ELN 2022 riskcategory | <.001 | |||
| Favorable | 13 (25%) | 13 (39%) | 0 | |
| Intermediate | 10 (19%) | 3 (9.1%) | 7 (37%) | |
| Adverse | 29 (56%) | 17 (52%) | 12 (63%) | |
| AML classification(ICC 202220 ) | <.001 | |||
| AML with recurrent genetic abnormalities | 14 (27%) | 14 (42%) | 0 | |
| AML with MDS-related gene mutations | 26 (50%) | 14 (42%) | 12 (63%) | |
| MDS/AML with MDS-related gene mutations | 4 (7.7%) | 4 (12%) | 0 | |
| AML with MDS-related cytogenetic abnormalities | 2 (3.8%) | 1 (3%) | 1 (5.3%) | |
| AML, NOS | 6 (12%) | 0 | 6 (32%) | |
| Cytogenetics | ||||
| Normal karyotype | 24 (46%) | 16 (48%) | 8 (42%) | .7 |
| Other karyotypes | ||||
| Trisomy 8 | 8 (15%) | 4 (12%) | 4 (21%) | .4 |
| Trisomy 11 | 4 (7.7%) | 2 (6.1%) | 2 (11%) | .6 |
| Trisomy 21 | 2 (3.8%) | 2 (6.1%) | 0 | .5 |
| Monosomy 7 | 2 (3.8%) | 2 (6.1%) | 0 | .5 |
| Molecular | ||||
| NPM1 | 13 (25%) | 13 (39%) | 0 | .002 |
| FLT3 | 3 (5.8%) | 3 (9%) | 0 | .3 |
| DNMT3A | 22 (44%) | 14 (45%) | 8 (42%) | .8 |
| RUNX1 | 15 (30%) | 10 (32%) | 5 (26%) | .7 |
| NRAS | 5 (10%) | 5 (16%) | 0 | .14 |
| BCOR | 10 (26%) | 4 (18%) | 6 (38%) | .3 |
| SRSF2 | 14 (38%) | 12 (55%) | 2 (13%) | .011 |
| ASXL1 | 8 (16%) | 5 (16%) | 3 (16%) | >.9 |
| Induction regimen | .8 | |||
| 7+3 | 28 (54%) | 17 (52%) | 11 (59%) | |
| 7+3+enasidenib | 11 (21%) | 7 (21%) | 4 (21%) | |
| 7+3+FLT3 inhibitor | 5 (10%) | 3 (9%) | 2 (10%) | |
| CPX-351 | 8 (15%) | 6 (18%) | 2 (10%) | |
| Induction intensity | .8 | |||
| Dauno60 | 30 (58%) | 18 (54%) | 12 (63%) | |
| Dauno90 | 12 (23%) | 8 (24%) | 4 (21%) | |
| Idarubicin 12 | 2 (4%) | 1 (3%) | 1 (5%) | |
| CPX-351 | 8 (15%) | 6 (18%) | 2 (11%) | |
Boldface values indicate statistically significant results with P < .05.
7+3, anthracycline + cytarabine; Dauno60, 60 mg/m2 of daunorubicin; Dauno90, 90 mg/m2 of daunorubicin; ICC, international consensus classification; Idarubicin 12, 12 mg/m2 of idarubicin; IQR, interquartile range; MDS, myelodysplastic syndrome; NOS, not otherwise specified.
Wilcoxon rank sum exact test; Pearson χ2 test; Fisher's exact test; Wilcoxon rank sum test.